{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:58:58Z","timestamp":1793105938288,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0318-y","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T06:59:22Z","timestamp":1512716362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":498,"title":["A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"9","author":[{"name":"for the SCarlet RoAD Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ostrowitzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Dorflinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Nikolcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Retout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Delmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Andjelkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"issue":"9","key":"318_CR1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"2","key":"318_CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101\u201312.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9533","key":"318_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"8","key":"318_CR4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734\u201346.","journal-title":"Lancet Neurol"},{"key":"318_CR5","doi-asserted-by":"crossref","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","DOI":"10.1016\/j.jalz.2011.03.003"},{"issue":"7","key":"318_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"8","key":"318_CR7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"318_CR8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198\u2013207.","journal-title":"Arch Neurol"},{"issue":"5","key":"318_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.410070516","volume":"7","author":"WG Rosen","year":"1980","unstructured":"Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5):486\u20138.","journal-title":"Ann Neurol"},{"issue":"11","key":"318_CR10","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"issue":"11","key":"318_CR11","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404\u201311.","journal-title":"Arch Neurol"},{"issue":"2","key":"318_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18\u00a0F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129\u201335.","journal-title":"Lancet Neurol"},{"issue":"5","key":"318_CR13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1109\/42.640753","volume":"16","author":"PA Freeborough","year":"1997","unstructured":"Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging. 1997;16(5):623\u20139.","journal-title":"IEEE Trans Med Imaging"},{"issue":"2","key":"318_CR14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.neuroimage.2009.12.059","volume":"50","author":"KK Leung","year":"2010","unstructured":"Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack Jr CR, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer\u2019s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50(2):516\u201323.","journal-title":"Neuroimage"},{"issue":"5","key":"318_CR15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund Jr RE, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517\u201326.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"318_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S1041610298005110","volume":"10","author":"P Davidsson","year":"1998","unstructured":"Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer\u2019s disease. Int Psychogeriatr. 1998;10(1):11\u201323.","journal-title":"Int Psychogeriatr"},{"issue":"11","key":"318_CR17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaneurol.2015.2075","volume":"72","author":"H Zetterberg","year":"2015","unstructured":"Zetterberg H, Blennow K. Neurogranin levels in cerebrospinal fluid: a new addition to the Alzheimer disease diagnostic toolbox. JAMA Neurol. 2015;72(11):1237\u20138.","journal-title":"JAMA Neurol"},{"issue":"10","key":"318_CR18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(10):1180\u201390.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"318_CR19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3174\/ajnr.A3475","volume":"34","author":"F Barkhof","year":"2013","unstructured":"Barkhof F, Daams M, Scheltens P, Brashear HR, Arrighi HM, Bechten A, et al. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol. 2013;34(8):1550\u20135.","journal-title":"AJNR Am J Neuroradiol"},{"key":"318_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.54","volume":"2","author":"I Delor","year":"2013","unstructured":"Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P. Modeling Alzheimer\u2019s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI. CPT Pharmacometrics Syst Pharmacol. 2013;2, e78.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"4","key":"318_CR21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370(4):322\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"318_CR22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8(1):18.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"318_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"318_CR24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72(11):1275\u201380.","journal-title":"JAMA Neurol"},{"issue":"7618","key":"318_CR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"16 Suppl","key":"318_CR26","doi-asserted-by":"crossref","first-page":"S1.003","DOI":"10.1212\/WNL.86.16_supplement.S1.003","volume":"86","author":"V Viglietta","year":"2016","unstructured":"Viglietta V, O\u2019Gorman J, Williams L, Tian Y, Sandrock A, Doody R, Salloway S, Barkhof F, et al. Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer\u2019s disease: phase 3 study design [abstract]. Neurology. 2016;86(16 Suppl):S1.003.","journal-title":"Neurology"},{"issue":"15","key":"318_CR27","first-page":"1460","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Farlow M, Aisen PS, Alzheimer\u2019s Disease Cooperative Study Data Analysis and Publication Committee. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med. 2014;370(15):1460.","journal-title":"N Engl J Med"},{"key":"318_CR28","unstructured":"European Medicines Agency (EMA). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease and other dementias. London: EMA; 23 Oct 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176827.pdf . Accessed 7 July 2017."},{"key":"318_CR29","unstructured":"Food and Drug Administration (FDA). Guidance for industry. Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease Silver Spring, MD: Center for Drug Evaluation and Research, FDA; Feb 2013. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm338287.pdf . Accessed 7 July 2017."},{"issue":"1 Suppl","key":"318_CR30","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jalz.2011.11.002","volume":"9","author":"JM Cedarbaum","year":"2013","unstructured":"Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2013;9(1 Suppl):S45\u201355.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"318_CR31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2011.01.005","volume":"7","author":"N Coley","year":"2011","unstructured":"Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer\u2019s disease trials. Alzheimers Dement. 2011;7(6):602\u201310.e2.","journal-title":"Alzheimers Dement"},{"key":"318_CR32","unstructured":"Edgar C, Rylands A, Volz D, Mertes M, Gruendl E, Fontoura P, Santarelli L, Lasser R. Comparative traditional psychometrics of cognitive and functional endpoints in a prodromal Alzheimer\u2019s disease population. Presented at Clinical Trials on Alzheimer\u2019s Disease conference, Barcelona, Spain, November 2015"},{"issue":"11","key":"318_CR33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 2015;72(11):1324\u201333.","journal-title":"JAMA Neurol"},{"issue":"1 Suppl","key":"318_CR34","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jalz.2012.01.005","volume":"9","author":"MM Williams","year":"2013","unstructured":"Williams MM, Storandt M, Roe CM, Morris JC. Progression of Alzheimer disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement. 2013;9(1 Suppl):S39\u201344.","journal-title":"Alzheimers Dement"}],"updated-by":[{"DOI":"10.1186\/s13195-018-0409-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T10:59:09Z","timestamp":1719658749000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0318-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"95"}}